Abstract 462P
Background
The aim of this study was to identify correlates of cognitive function among cancer survivors attending rehabilitation in a community setting.
Methods
Participants were 35 cancer patients who had reported memory issues and were screened by an occupational therapist for cognitive dysfunction. Using baseline data, descriptive and bivariate analyses were performed to detail the cognitive function of study sample and to identify its correlates.
Results
Study sample was predominantly female (94.7%) with breast cancer (65.8%) who had received chemotherapy (77.1%) and hormonal therapy (51.5%). Mean age was 53.8 ± 10.3 years and mean years since diagnosis was 4.9 ± 3.3 years. Mean scores of cognitive performances were within the norms for attention (digit span forward test; 7.5 ± 1.4), working memory (digit span backward test; 5.4 ± 1.3), processing speed (trail making test A; 25.1 ± 5.5), and executive function (trail making test B; 68.3 ± 33.6). Mean scores of perceived cognitive ability (15.5 ± 4.1) and cognitive-related quality of life (9.8 ± 3.7), measured by the FACT-Cog, were below the norms. Cancer survivors with more years since diagnosis performed better in executive function (r = .45). Poorer working memory (r = -.38) and lower cognitive-related quality of life (r = -.41) were also found to associate with increased fatigue intensity. Although sleep duration and distress rating were not related to cognitive function, shorter sleep duration (r = -.35) and higher distress rating (r = .37) correlated with higher fatigue intensity. All results were statistically significant at p < 0.05.
Conclusions
Cancer survivors may report reduced perceived cognitive ability and cognitive-related quality of life despite adequate performance on objective tests. This discrepancy could be due to the relationship of fatigue to working memory. Global evaluation of cognitive function considers cognitive performance during periods of more intense fatigue while objective tests provide information on cognitive performance when tested at a particular time and fatigue level. Managing fatigue including addressing distress and sleep issues may be potential strategies that can be employed to support cognitive function.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract